Michelle A. Rudek, Ph.D.
Affiliations: | 2001 | Virginia Commonwealth University, Richmond, VA, United States |
Area:
Pharmacy, Pharmacology, OncologyGoogle:
"Michelle Rudek"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| William D. Figg | grad student | 2001 | VCU | |
| (Evaluation of the pharmacokinetic -pharmacodynamic relationship for the matrix metalloproteinase inhibitory effect of COL-3 following oral administration to patients with refractory metastatic cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Baker SD, Bates SE, Brooks GA, et al. (2023) Testing: Time to Put Patient Safety First. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2202364 |
| Connolly RM, Laille E, Vaishampayan U, et al. (2020) Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Murphy AG, Zahurak M, Shah M, et al. (2020) A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer. Clinical and Translational Science |
| Grossman SA, Romo CG, Rudek MA, et al. (2020) Baseline Requirements for Novel Agents Being Considered for Phase II/III Brain Cancer Efficacy Trials:Conclusions from the Adult Brain Tumor Consortium's First Workshop on CNS Drug Delivery. Neuro-Oncology |
| Pratz KW, Rudek MA, Smith BD, et al. (2019) A prospective study of peri-transplant sorafenib for FLT3-ITD AML patients undergoing allogeneic transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation |
| Kurzrock R, Ball DW, Zahurak ML, et al. (2019) The VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Gaillard SL, Zahurak M, Sharma A, et al. (2019) A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors. Cancer |
| Saif MW, Rosen L, Rudek MA, et al. (2019) Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment (PI: Dr Saif). British Journal of Clinical Pharmacology |
| Rubinstein PG, Moore PC, Bimali M, et al. (2019) Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085 Blood. 134: 130-130 |
| Bharathy N, Berlow NE, Wang E, et al. (2018) The HDAC3-SMARCA4-miR-27a axis promotes expression of the fusion oncogene in rhabdomyosarcoma. Science Signaling. 11 |